On February 14, 2025, the Food and Drug Administration sanctioned vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cel...
On February 11, 2025, the Food and Drug Administration authorized the use of brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in conjunction with lenalidomide and a rituximab produc...
On February 11, 2025, the Food and Drug Administration sanctioned mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients aged 2 years and older di...
On January 21, 2025, the Food and Drug Administration sanctioned treosulfan (Grafapex, medac GmbH), an alkylating agent, in conjunction with fludarabine as a preparative regimen for allogeneic hematop...
On January 27, 2025, the Food and Drug Administration sanctioned fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or metastatic hormone receptor (HR)-positive, HER2-low...
On January 16, 2025, the Food and Drug Administration sanctioned the use of sotorasib (Lumakras, Amgen Inc.) in conjunction with panitumumab (Vectibix, Amgen Inc.) for adult patients diagnosed with KR...
April 2023: Retifanlimab-dlwr (Zynyz, Incyte Corporation) received fast approval from the Food and Drug Administration to treat adult patients with metastatic or recurrent locally advanced Merkel cel...